Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk-proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024.
Saved in:
| Title: | Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk-proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024. |
|---|---|
| Authors: | Manfrin A; Medicines and Healthcare Products Regulatory Agency, UK., Lee K; Medicines and Healthcare Products Regulatory Agency, UK., Cacou C; Medicines and Healthcare Products Regulatory Agency, UK., Pound J; Medicines and Healthcare Products Regulatory Agency, UK., Harnden A; Medicines and Healthcare Products Regulatory Agency, UK., Raine J; Medicines and Healthcare products Regulatory Agency (Retired), UK., Pirmohamed M; University of Liverpool, UK. |
| Source: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2026 Mar; Vol. 92 (3), pp. 822-829. Date of Electronic Publication: 2025 Oct 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1365-2125 |
|---|---|
| DOI: | 10.1002/bcp.70308 |
